Headlines Covid-19 Specialties Trending Feeds Videos

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

Mashup Score: 75


www.prnewswire.com - /PRNewswire/ — Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term
  • This is an important part of the picture. Congrats for getting this trial done in a vulnerable population. Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, r... https://t.co/pfeeyvYxQr